Evidence map›Paper›PMID 42325909›Full record

ReviewDrug design, development and therapy2026

Recent Advances in the Study of Traditional Chinese Medicine in Reversing Hepatic Fibrosis Through the Regulation of Hepatic Stellate Cells Apoptosis Pathways.

Ruihan Cheng, Baolong Li

Abstract readReview
In one paragraph

Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ruihan ChengDrug Safety Evaluation Center, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang Province, 150006, People's Republic of China.ORCID 0009-0000-4264-2819
Baolong LiDrug Safety Evaluation Center, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang Province, 150006, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatic fibrosis is a pathological manifestation in which hepatic stellate cells are activated by inflammatory stimuli and produce excessive extracellular matrix, leading to excessive intrahepatic collagen deposition. As the core effector cells of hepatic fibrosis, hepatic stellate cells have multiple cellular states, including quiescent, activated, and quiescence-like dysfunctional states. In hepatic fibrosis, they can exert functions such as pro-inflammatory effects, strong proliferation, maintenance of permanent activation state, and resistance to cell death by activating multiple relevant signaling pathways under their different states. Therefore, inducing multiple death pathways in hepatic stellate cells and restoring their dysfunctional, quiescent, and senescent states are crucial for inhibiting hepatic fibrosis. The active ingredients and compound formulations of traditional Chinese medicine have advantages such as multi-pathway effects and low metabolic burden in the treatment of hepatic fibrosis, and significant progress has been made in studies on regulating hepatic stellate cells death and reversing hepatic fibrosis, though challenges remain such as identifying specific active components, clarifying mechanisms, and improving experimental models to better simulate the liver's multicellular environment.

Indexed as

ApoptosisDrugs, Chinese HerbalHepatic Stellate CellsLiver CirrhosisMedicine, Chinese TraditionalAnimalsHumansSignal TransductionDrugs, Chinese Herbalautophagyferroptosishepatic fibrosishepatic stellate cellmitophagynuclear factor-kappa Btraditional Chinese medicine

Identifiers

PMID42325909
PMCPMC13281759

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.